ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Cristal Therapeutics Initiates Phase 2 Clinical Trial of Innovative CriPec® Nanomedicine Drug Candidate in Ovarian Cancer
November 10, 2018CPC634 is a new drug modality. It combines CriPec® nanoparticles with docetaxel (Taxotere®), a clinically validated chemotherapy, as its therapeutic payload. This nanomedicine candidate has been designed to enable enhanced tumour accumulation and localise
Pharma Sources Insight January 2025
